NVO241227C120000
- 0.02
- 0.000.00%
Novo-Nordisk A/S Newsroom
The world's first oral GLP-1 receptor agonist, Novo-Nordisk A/S, has been fully launched in China.
On January 11, Gelonghui reported that Novo-Nordisk A/S announced the comprehensive launch of its Innovative Drug, Ozempic (semaglutide tablets), in China today. As the first oral GLP-1RA, Ozempic combines SNAC technology to achieve significant benefits such as lowering blood sugar, weight loss, blood pressure reduction, and lipid regulation. The once-daily oral administration will improve patient adherence, creating a new era in the treatment of type 2 diabetes, helping achieve quality blood sugar targets and comprehensive metabolic management, bringing new hope to 0.14 billion diabetes patients in China.
Express News | Novo-Nordisk A/S is confident in the economic prospects of China and its development in the country, and is willing to continue investing in the Chinese market.
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading
U.S. stocks are experiencing fluctuations | Novo-Nordisk A/S (NVO.US) is rising nearly 2% against the trend while developing weight-loss drugs using AI.
On Friday, Novo-Nordisk A/S (NVO.US) rose nearly 2% against the trend, closing at $86.77.
Novo Holdings Invests in $200M Series A for Windward Bio Launch to Advance Long-acting Treatments for Asthma and COPD
HIMS Downgraded, Agilon Upgraded at Citi in 2025 Health Tech Review
Novo Nordisk Still a Buy, But Patience May Be Needed -- Market Talk
U.S. Stock Outlook | Non-farm payroll data exceeded expectations, leading to a short-term plunge in the three major futures indices; high-performing stocks surged, with pharmacy stock WBA rising over 13% in pre-market, and Delta Air Lines climbing over 9%
NVIDIA slightly fell before the market opened, and AMD dropped over 2% before the market opened, as the USA plans to tighten the export of AI Chips from NVIDIA and AMD; several Federal Reserve voting members have spoken out, hinting at a pause in interest rate cuts; sources say that the USA Treasury is expected to release a statement detailing new sanctions on Russian oil later on Friday.
Morgan Stanley's outlook for the top ten investment trends in 2025: the revival of nuclear energy, the AI revolution in the financial Industry, quantum computing, oral weight loss medications...
Morgan Stanley pointed out that historically, popular themes with strong profit momentum tend to have a strong sustainability, such as AI, defense spending, and obesity drugs; negative prices and quantum computing are expected to emerge as new investment hotspots.
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far
Euro Stocks Can Offer a Lesson in High Concentration for the U.S. – Goldman
Drugs Not Selected for Medicare Price Negotiation Nearly Doubled - Report
NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy
Medicare Will Pay for Zepbound for Some Patients. The Costs Could Be Huge -- Barrons.com
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
Correction to Novo Nordisk, Valo Health Article on Wednesday
Novo-Nordisk A/S expands its cooperation with Valo Health to develop weight loss medications using AI.
On January 9, Glorix reported that Novo-Nordisk A/S and the USA technology company Valo Health agreed to expand their collaboration agreement to develop up to 11 drugs in 2023, utilizing human data and AI to develop up to 20 new therapies targeting obesity, type 2 diabetes, and cardiovascular diseases. According to the terms of the extended agreement, Valo is entitled to receive a total of up to $0.19 billion in short-term payments and about $4.6 billion in development milestone payments.
Donald Trump Wants Tariffs on Denmark Next. These Industries Would Be Hit Most. -- Barrons.com
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading
Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals